HeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...

The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five ...

Despite a net loss and cash constraints, HeartBeam Inc (BEAT) remains optimistic about FDA clearance and its groundbreaking ECG technology. As the U.S. stock market experiences a downturn ...

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia assessment The Company is gearing up for an Early Access Program to gain initial ...

Heartbeam Inc. received U.S. FDA 510(K) clearance for its portable, non-invasive electrocardiogram system that enables on-the-go recording of heart signals. The cable-free, credit card-sized device ...

HeartBeam (NASDAQ: BEAT), a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025 ...

SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a $56.5 million market cap pioneer in medical technology currently trading at $2.12 per share, has announced the submission of a 510(k ...

Overview: HeartBeam, Inc. is a medical technology company that develops and commercializes ambulatory electrocardiogram solutions for cardiac disease detection and monitoring in various settings, with ...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today ...